title: [Differential therapy of heart failure. Which drug for which patient?].
abstract: The implementation of guidelines for medical therapy of heart failure may be problematic for the following reasons: 1. Elderly patients and women were underrepresented in large clinical trials which may limit their therapeutic impact in these patients. 2. Therapeutic decisions are influenced by co-morbidities like renal failure, obstructive airway disease (COLD, Asthma), stroke, and diabetes mellitus. We therefore discuss the differential therapy of heart failure in view of particular patient subgroups.
authors.affiliation: Herzzentrum, Georg-August-Universität Göttingen.
authors.forename: W
authors.initials: W
authors.lastname: Schillinger
authors.forename: H P
authors.initials: HP
authors.lastname: Hermann
authors.forename: G
authors.initials: G
authors.lastname: Hasenfuss
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003661:Decision Support Techniques; D006333:Heart Failure / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors